Investigational Drug Information for PF-06651600
✉ Email this page to a colleague
What is the development status for investigational drug PF-06651600?
PF-06651600 is an investigational drug.
There have been 34 clinical trials for PF-06651600.
The most recent clinical trial was a Phase 3 trial, which was initiated on July 18th 2019.
The most common disease conditions in clinical trials are Alopecia Areata, Alopecia, and Arthritis, Rheumatoid. The leading clinical trial sponsors are Pfizer, Emma Guttman, and Icahn School of Medicine at Mount Sinai.
There is one US patent protecting this investigational drug and fifty-one international patents.
Summary for PF-06651600
US Patents | 1 |
International Patents | 51 |
US Patent Applications | 9 |
WIPO Patent Applications | 8 |
Japanese Patent Applications | 2 |
Clinical Trial Progress | Phase 3 (2019-07-18) |
Vendors | 42 |
Recent Clinical Trials for PF-06651600
Title | Sponsor | Phase |
---|---|---|
A Study to Assess Two Forms of The Study Medicine (Ritlecitinib) in Healthy Adult Participants | Pfizer | Phase 1 |
Ritlecitinib in CTCL | Pfizer | Phase 2 |
Ritlecitinib in CTCL | Icahn School of Medicine at Mount Sinai | Phase 2 |
Clinical Trial Summary for PF-06651600
Top disease conditions for PF-06651600
Top clinical trial sponsors for PF-06651600
US Patents for PF-06651600
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
PF-06651600 | ⤷ Try a Trial | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides | Pfizer Inc. (New York, NY) | ⤷ Try a Trial |
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for PF-06651600
Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
---|---|---|---|---|
PF-06651600 | Argentina | AR099363 | 2033-12-05 | ⤷ Try a Trial |
PF-06651600 | Australia | AU2014358792 | 2033-12-05 | ⤷ Try a Trial |
PF-06651600 | Brazil | BR112016012262 | 2033-12-05 | ⤷ Try a Trial |
PF-06651600 | Canada | CA2932425 | 2033-12-05 | ⤷ Try a Trial |
PF-06651600 | Chile | CL2016001216 | 2033-12-05 | ⤷ Try a Trial |
PF-06651600 | China | CN106061973 | 2033-12-05 | ⤷ Try a Trial |
PF-06651600 | China | CN107417684 | 2033-12-05 | ⤷ Try a Trial |
>Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |